Last reviewed · How we verify

Non-steroidal anti-inflammatory drug

Sucampo Pharma Americas, LLC · Phase 2 active Small molecule

Non-steroidal anti-inflammatory drug is a Small molecule drug developed by Sucampo Pharma Americas, LLC. It is currently in Phase 2 development. Also known as: Standard Care.

At a glance

Generic nameNon-steroidal anti-inflammatory drug
Also known asStandard Care
SponsorSucampo Pharma Americas, LLC
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Non-steroidal anti-inflammatory drug

What is Non-steroidal anti-inflammatory drug?

Non-steroidal anti-inflammatory drug is a Small molecule drug developed by Sucampo Pharma Americas, LLC.

Who makes Non-steroidal anti-inflammatory drug?

Non-steroidal anti-inflammatory drug is developed by Sucampo Pharma Americas, LLC (see full Sucampo Pharma Americas, LLC pipeline at /company/sucampo-pharma-americas-llc).

Is Non-steroidal anti-inflammatory drug also known as anything else?

Non-steroidal anti-inflammatory drug is also known as Standard Care.

What development phase is Non-steroidal anti-inflammatory drug in?

Non-steroidal anti-inflammatory drug is in Phase 2.

Related